The CXCR2 antagonist SB225002 stalls CML cells in the G2/M phase, inhibiting proliferation while reducing mTOR, c-Myc, and BCR-ABL expression. Here, CXCR2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.